Quantum-Si Inc
quantum-si.comWhat Do They Do?
Sells protein-sequencing instruments, consumable kits and analysis software to research laboratories.
10-K for FY2025, filed Mar 3, 2026
How Do They Make Money?
Customers pay for sequencing instruments and consumables when goods ship or are delivered. Maintenance contracts provide service over time, while advanced training is a one-time service.
10-K for FY2025, filed Mar 3, 2026
-
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗
$2.4M
-
10-K for FY2025, filed Mar 3, 2026
$2.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
94% |
Product, FY2025
$2.3M Sources
|
Sold outright |
|
Service
Mix
|
6.2% |
Service, FY2025
$150K Sources
|
Mix |
Who Are Their Customers?
Researchers at academic and other laboratories, biopharma and contract development and manufacturing organizations, and government and industrial users are target customers. The company sells directly in the United States, through direct sales and distributors in Europe, and through distributors in certain other markets.
10-K for FY2025, filed Mar 3, 2026Build our commercial infrastructure globally. We are continuing to build our commercial and operational infrastructure to sell and support…View ↗
As we continue to commercialize our platforms, we plan to build out our commercial infrastructure to sell and support our products, across…View ↗
Today, our protein sequencing platforms, Platinum and Platinum Pro, address these market challenges in two distinct ways. First, our…View ↗
Do Revenues Turn Into Profits?
No. It lost $101.3M in FY2025.
10-K for FY2025, filed Mar 3, 2026
−$116.1MView ↗
10-K for FY2025, filed Mar 3, 2026
−$101.3MView ↗
10-K for FY2025, filed Mar 3, 2026
−$97.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$23.5MView ↗
- ▼ −18% (Loss)
- vs −$28.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Aug 13, 2026
Quantum-Si moves the anticipated Proteus launch later
It added an integrated instrument design cycle and moved the anticipated commercial launch to Q2 2027.
Sources
8-K, filed Aug 13, 2026
Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and…View ↗
-
Jul 24, 2026
Nasdaq notified Quantum-Si of a listing-rule deficiency
The company has until January 19, 2027 to regain compliance; the notice had no immediate effect on stock listing or trading.
Sources
8-K, filed Jul 24, 2026
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180…View ↗
Added platforms
The newer report adds Platinum Pro to the commercial line and describes Proteus as the next-generation platform under development; the earlier report described Platinum and a planned Carbon sample-preparation instrument.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 3, 2026We are an innovative life sciences company with the mission of transforming biomarker discovery and clinical research by providing…View ↗
Loading...
